$MRUS
Merus N.V. Stock $mrus

$mrus Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000156459022018867 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$11.66M	$8.350M
YoY Change	39.58%	32.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.75M	$9.330M
YoY Change	25.97%	5.07%
% of Gross Profit
Research & Development	$26.98M	$20.81M
YoY Change	29.65%	22.48%
% of Gross Profit
Depreciation & Amortization	$351.0K	$324.0K
YoY Change	8.33%	25.58%
% of Gross Profit
Operating Expenses	$38.73M	$30.14M
YoY Change	28.5%	16.51%
Operating Profit	-$27.07M	-$21.79M
YoY Change	24.25%	11.35%
Interest Expense	$7.836M	$12.12M
YoY Change	-35.35%	282.33%
% of Operating Profit
Other Income/Expense, Net	$8.294M	$11.68M
YoY Change	-29.01%	269.16%
Pretax Income	-$18.78M	-$10.11M
YoY Change	85.84%	-38.4%
Income Tax	$114.0K	$49.00K
% Of Pretax Income
Net Earnings	-$18.89M	-$10.15M
YoY Change	86.06%	-38.46%
Net Earnings / Revenue	-162.1%	-121.6%
Basic Earnings Per Share	-$0.43
Diluted Earnings Per Share	-$434.4K	-$280.3K
COMMON SHARES
Basic Shares Outstanding	43.49B	38.13M
Diluted Shares Outstanding	43.49B

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$358.8M	$374.4M
YoY Change	-4.16%	74.95%
Cash & Equivalents	$194.6M	$327.1M
Short-Term Investments	$164.2M	$47.20M
Other Short-Term Assets	$2.434M	$1.366M
YoY Change	78.18%	-27.3%
Inventory
Prepaid Expenses
Receivables	$2.671M	$294.0K
Other Receivables	$496.0K	$100.0K
Total Short-Term Assets	$379.7M	$386.1M
YoY Change	-1.66%	71.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.843M	$3.766M
YoY Change	81.7%	-55.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$25.47M
YoY Change
Other Assets	$3.225M	$1.872M
YoY Change	72.28%	33.71%
Total Long-Term Assets	$37.77M	$11.83M
YoY Change	219.38%	-5.4%
TOTAL ASSETS
Total Short-Term Assets	$379.7M	$386.1M
Total Long-Term Assets	$37.77M	$11.83M
Total Assets	$417.5M	$397.9M
YoY Change	4.91%	67.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.388M	$3.715M
YoY Change	45.03%	9.26%
Accrued Expenses	$22.44M	$23.50M
YoY Change	-4.51%	93.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$61.52M	$52.96M
YoY Change	16.18%	48.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$58.50M	$108.5M
YoY Change	-46.08%	23.58%
Total Long-Term Liabilities	$58.50M	$108.5M
YoY Change	-46.08%	23.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$61.52M	$52.96M
Total Long-Term Liabilities	$58.50M	$108.5M
Total Liabilities	$120.0M	$161.4M
YoY Change	-25.64%	30.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$485.8M	-$410.3M
YoY Change	18.4%	23.92%
Common Stock	$798.6M	$647.1M
YoY Change	23.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$297.5M	$236.5M
YoY Change
Total Liabilities & Shareholders Equity	$417.5M	$397.9M
YoY Change	4.91%	67.21%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$18.89M	-$10.15M
YoY Change	86.06%	-38.46%
Depreciation, Depletion And Amortization	$351.0K	$324.0K
YoY Change	8.33%	25.58%
Cash From Operating Activities	-$46.40M	$19.34M
YoY Change	-339.86%	-176.58%
INVESTING ACTIVITIES
Capital Expenditures	$342.0K	$157.0K
YoY Change	117.83%	6.08%
Acquisitions
YoY Change
Other Investing Activities	-$625.0K	-$2.520M
YoY Change	-75.2%	-34.38%
Cash From Investing Activities	-$967.0K	-$2.674M
YoY Change	-63.84%	-32.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$129.6M
YoY Change	-100.0%	-79104.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	879.0K	150.5M
YoY Change	-99.42%	34250.91%
NET CHANGE
Cash From Operating Activities	-46.40M	19.34M
Cash From Investing Activities	-967.0K	-2.674M
Cash From Financing Activities	879.0K	150.5M
Net Change In Cash	-47.36M	164.1M
YoY Change	-128.87%	-615.7%
FREE CASH FLOW
Cash From Operating Activities	-$46.40M	$19.34M
Capital Expenditures	$342.0K	$157.0K
Free Cash Flow	-$46.74M	$19.19M
YoY Change	-343.61%	-175.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-37773
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Yalelaan 62
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	3584 CM
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Utrecht
CY2022Q1	dei	Entity Address Country EntityAddressCountry	NL
CY2022Q1	dei	City Area Code CityAreaCode	+31 85
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	016 2500
CY2022Q1	dei	Security12b Title Security12bTitle	Common shares, nominal value €0.09 per share
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43550059
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	194575000
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	164239000
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2671000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	4609000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18248000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7448000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	379733000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	424179000
CY2022Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	25466000
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	20297000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1491000
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33696000
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	18048000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	61523000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71898000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1874000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2257000
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	56630000
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	10962000
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	55282000
CY2022Q1	us-gaap	Liabilities Liabilities	120027000
CY2021Q4	us-gaap	Liabilities Liabilities	140399000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.09
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	67500000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43549325
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43549325
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	4489000
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	794074000
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15269000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-485821000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	297473000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	417500000
CY2022Q1	us-gaap	Revenues Revenues	11655000
CY2021Q1	us-gaap	Revenues Revenues	8350000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26975000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20806000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11753000
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9333000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	38728000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	30139000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27073000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21789000
CY2022Q1	mrus	Investment Income Expense Interest InvestmentIncomeExpenseInterest	106000
CY2021Q1	mrus	Investment Income Expense Interest InvestmentIncomeExpenseInterest	-82000
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7730000
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	12203000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	458000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-437000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8294000
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11684000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5334000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3400000
CY2022Q1	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-297000
CY2021Q1	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-35000
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	337000
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	369000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3549000
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	340000
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	-14000
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	17000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12152000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1574000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7635000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	756000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1146000
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1130000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8663000
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	37396000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46397000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19343000
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	55142000
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20645000
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	54517000
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	18128000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	342000
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	157000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-967000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2674000
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	129568000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	879000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4697000
CY2022Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0
CY2021Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	285000
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	66000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	25000
CY2022Q1	mrus	Non Cash Issuance Of Stock Options NonCashIssuanceOfStockOptions	0
CY2021Q1	mrus	Non Cash Issuance Of Stock Options NonCashIssuanceOfStockOptions	572000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	194575000
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	327137000
CY2022Q1	mrus	Restricted Cash And Non Current Other Assets RestrictedCashAndNonCurrentOtherAssets	312000
CY2021Q1	mrus	Restricted Cash And Non Current Other Assets RestrictedCashAndNonCurrentOtherAssets	201000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194887000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	327338000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	102263000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	129403000
CY2021Q1	mrus	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested	4824000
CY2021Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	285000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3400000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9391000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-10154000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	236537000
CY2022Q1	mrus	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested	879000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6048000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-18893000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	297473000
CY2022Q1	mrus	Prepaid General And Administrative Expenses PrepaidGeneralAndAdministrativeExpenses	5269000
CY2021Q4	mrus	Prepaid General And Administrative Expenses PrepaidGeneralAndAdministrativeExpenses	2760000
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Overview </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus N.V. is a clinical-stage oncology company developing innovative antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the “Company”).</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has generated an accumulated deficit of $485.8 million as of March 31, 2022. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved antibody candidate.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations, business development and licensing opportunities with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company’s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the Company’s current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities of $$384.3 million as of March 31, 2022, will fund the Company’s operations beyond 2024.</p>
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-485800000
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	384300000
CY2022Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	194937000
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	194971000
CY2022Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	194165000
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	194773000
CY2022Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	194937000
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	194971000
CY2022Q1	mrus	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	10049000
CY2021Q4	mrus	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	2146000
CY2022Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	496000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	367000
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2434000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2175000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18248000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7448000
CY2022Q1	mrus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	15593000
CY2021Q4	mrus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	15174000
CY2022Q1	mrus	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1994000
CY2021Q4	mrus	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	4861000
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2695000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1362000
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	666000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1109000
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	20948000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	22506000
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49000
CY2022Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-171000
CY2021Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-226000
CY2022Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-52000
CY2021Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-94000
CY2022Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-223000
CY2021Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-320000
CY2022Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	238000
CY2021Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	261000
CY2022Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	99000
CY2021Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	108000
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	337000
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	369000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	385000
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	76000
CY2022Q1	us-gaap	Lease Cost LeaseCost	461000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	399000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5334000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3400000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Black Scholes option pricing model
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.92
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1522250
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.762
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	100000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	200000

Files In Submission

Name	View Source	Status
0001564590-22-018867-index-headers.html	Edgar Link	pending
0001564590-22-018867-index.html	Edgar Link	pending
0001564590-22-018867.txt	Edgar Link	pending
0001564590-22-018867-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gtiwlbewmtri000001.jpg	Edgar Link	pending
gtiwlbewmtri000002.jpg	Edgar Link	pending
gtiwlbewmtri000003.jpg	Edgar Link	pending
gtiwlbewmtri000004.jpg	Edgar Link	pending
gtiwlbewmtri000005.jpg	Edgar Link	pending
gtiwlbewmtri000006.jpg	Edgar Link	pending
gtiwlbewmtri000007.jpg	Edgar Link	pending
gtiwlbewmtri000008.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrus-10q_20220331.htm	Edgar Link	pending
mrus-10q_20220331_htm.xml	Edgar Link	completed
mrus-20220331.xsd	Edgar Link	pending
mrus-20220331_cal.xml	Edgar Link	unprocessable
mrus-20220331_def.xml	Edgar Link	unprocessable
mrus-20220331_lab.xml	Edgar Link	unprocessable
mrus-20220331_pre.xml	Edgar Link	unprocessable
mrus-ex101_101.htm	Edgar Link	pending
mrus-ex102_102.htm	Edgar Link	pending
mrus-ex311_6.htm	Edgar Link	pending
mrus-ex321_7.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRUS
Merus N.V. Stock $mrus

2022 Q1 Form 10-Q Financial Statement

#000156459022018867 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRUS Merus N.V. Stock $mrus

2022 Q1 Form 10-Q Financial Statement

#000156459022018867 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRUS
Merus N.V. Stock $mrus